Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
AGC Biologics has announced the appointment of Christopher Holt as Site Head/General Manager of its Bothell, Washington operations.
read more
Tuesday, October 08, 2019
AGC Biologics announced the appointment of Jeffery D. Mowery as Site Head/General Manager of the Copenhagen, Denmark facility.
read more
AGC Biologics will supply bulk drug substance for the launch of Portola Pharmaceuticals' Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo].
read more
Wednesday, August 09, 2023
AGC Biologics announced the completion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site.
read more
AGC Biologics has entered into a commercial supply agreement with MacroGenics for the manufacture of margetuximab, a clinical-stage, novel immune-optimized monoclonal antibody.
read more
AGC Biologics announces it has expanded its partnership with Rocket Pharmaceuticals.
read more
Monday, December 16, 2019
AGC Biologics is expanding its CDMO services with plasmid DNA (pDNA) offerings from its Heidelberg site in Germany.
read more
AGC Biologics announced the addition of a new building complex that will house the company’s global headquarters in Bothell, Washington.
read more
Monday, November 18, 2019
AGC Biologics announced their development and manufacturing capabilities at their Seattle, Washington and Copenhagen, Denmark facilities will be expanded.
read more
Wednesday, February 04, 2026
The Seattle facility of AGC Biologics has received a Good Manufacturing Practices Certification from Agência Nacional de Vigilância Sanitária (Anvisa), Brazil’s health regulatory authority.
read more
Tuesday, January 24, 2023
AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site.
read more
Wednesday, February 09, 2022
AGC Biologics announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.
According to a recent news release from Pfizer and BioNTech, the ...
read more
AGC Biologics, a biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, Colorado, ...
read more
Tuesday, November 25, 2025
Under this agreement AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s two novel candidates designed to address progressive and irreversible vision loss where there are currently no approved therapies.
read more
AGC Biologics is partnering with clinical-stage biotech company Molecular Partners to develop a new class of custom-built protein therapeutics known as DARPin.
read more